Research programme: gastrointestinal therapeutics - Ligand Pharmaceuticals
Latest Information Update: 27 Jun 2024
At a glance
- Originator Novan Inc
- Class Anti-inflammatories; Nitrogen oxides
- Mechanism of Action Nitric oxide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Gastrointestinal disorders
Most Recent Events
- 27 Jun 2024 Discontinued - Preclinical for Gastrointestinal disorders in USA (unspecified route) (Pelthos Therapeutics pipeline; June 2024)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA
- 01 Jan 2019 Preclinical trials in Gastrointestinal disorders in USA (unspecified route)